Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Infect Dis ; 20(1): 941, 2020 Dec 10.
Artículo en Inglés | MEDLINE | ID: mdl-33302895

RESUMEN

BACKGROUND: A more time saving, convenient, reproducible, and scalable method is needed to assess total HIV-1 DNA levels. METHODS: Frozen whole blood and peripheral blood mononuclear cell (PBMC) samples both 200 µl at the same point were used to detect total HIV-1 DNA. Automatic extraction of total HIV-1 DNA was used to ensure the consistency of sample extraction efficiency. The detection reagent was HIV-1 DNA quantitative detection kit and real-time quantitative PCR was utilized. RESULTS: Of the 44 included patients, 42 were male and 2 were female, with a median age of 33 years. Thirty-three cases were collected after receiving antiviral treatment, with a median duration of treatment of 3 months, and the other 11 cases were collected before antiviral treatment. The median viral load was 1.83 log10 copies/mL, the median CD4 and CD8 count were 94 and 680 cells/µL, and the median CD4/CD8 ratio was 0.18. The results of the two samples were 3.02 ± 0.39 log10 copies/106 PBMCs in PBMC samples and 3.05 ± 0.40 log10 copies/106 PBMCs in whole blood samples. The detection results of the two methods were highly correlated and consistent by using paired t test (P = 0.370), pearson correlation (r = 0.887, P < 0.0001) and intra-group correlation coefficient (ICC = 0.887, P < 0.0001) and bland-altman [4.55% points were outside the 95% limits of agreement (- 0.340 ~ 0.390)]. CONCLUSIONS: The results of the whole blood sample test for total HIV-1 DNA are consistent with those of PBMC samples. In a clinical setting it is recommended to use whole blood samples directly for the evaluation of the HIV reservoir.


Asunto(s)
ADN Viral/sangre , Infecciones por VIH/sangre , Infecciones por VIH/diagnóstico , VIH-1/genética , Leucocitos Mononucleares/virología , Adulto , Fármacos Anti-VIH/uso terapéutico , Relación CD4-CD8 , ADN Viral/análisis , Femenino , Estudios de Seguimiento , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Humanos , Masculino , Reacción en Cadena en Tiempo Real de la Polimerasa , Estudios Retrospectivos , Carga Viral/efectos de los fármacos
2.
Chin Med J (Engl) ; 130(2): 224-230, 2017 01 20.
Artículo en Inglés | MEDLINE | ID: mdl-28091416

RESUMEN

OBJECTIVE: To review the recent literatures related to the factors associated with the size of the HIV reservoir and their clinical significance. DATA SOURCES: Literatures related to the size of HIV DNA was collected from PubMed published from 1999 to June 2016. STUDY SELECTION: All relevant articles on the HIV DNA and reservoir were collected and reviewed, with no limitation of study design. RESULTS: The composition and development of the HIV-1 DNA reservoir in either treated or untreated patients is determined by integrated mechanism comprising viral characteristics, immune system, and treatment strategies. The HIV DNA reservoir is a combination of latency and activity. The residual viremia from the stochastic activation of the reservoir acts as the fuse, continuing to stimulate the immune system to maintain the activated microenvironment for the rebound of competent virus once treatment with antiretroviral therapy is discontinued. CONCLUSION: The size of the HIV-1 DNA pool and its composition has great significance in clinical treatment and disease progression.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , ADN Viral/genética , Infecciones por VIH/tratamiento farmacológico , VIH-1/patogenicidad , Femenino , Infecciones por VIH/genética , VIH-1/efectos de los fármacos , VIH-1/genética , Humanos , Masculino , Carga Viral/efectos de los fármacos , Carga Viral/genética , Viremia/tratamiento farmacológico , Viremia/genética
3.
Yao Xue Xue Bao ; 41(7): 608-14, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17007351

RESUMEN

AIM: To develop a rapid and inexpensive method for purification of human albumin, a method of immunomagnetic microspheres (IMMS) based on enzyme-linked immunosorbent assay (ELISA) for the purification of human albumin from human serum. METHODS: Polystyrene magnetic microspheres with carboxyl groups as carriers were prepared, and then the carboxyl groups on the surface of the microspheres were activated by ethylcarbodiimide (EDC). Finally rabbit anti-human serum albumin (HSA) antibodies were covalently bound to it and the complex can specifically capture HSA. After the procedure of capturing HSA, through taking rabbit anti-human albumin protein antibodies as a capture antibody, and goat anti-human albumin protein antibodies as a detection antibody, an ELISA on IMMS was developed, which can determine the recovery yield of HSA from the human serum. RESULTS: The result of the experiment was that the recovery of human albumin with IMMS was (86 +/- 4)%, and IMMS were reused for two other purifying cycles, the results of which were (69.0 +/- 0.6)% and (40.8 +/- 0.8)%, and the purity of the product was about 90%. CONCLUSION: The results above prove that the immunomagnetic purifiying strategy was shown to be efficient and offers an new thought for a large scale production of high-purity HSA.


Asunto(s)
Separación Inmunomagnética/métodos , Microesferas , Albúmina Sérica/aislamiento & purificación , Ensayo de Inmunoadsorción Enzimática/instrumentación , Ensayo de Inmunoadsorción Enzimática/métodos , Humanos , Poliestirenos/química , Reproducibilidad de los Resultados , Albúmina Sérica/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA